RxDoctor Payments Data

Theodore Otti, MD

Nephrology · Richmond Heights, MONPI 1316950884

Payments from drug & device makers

$1,309in general payments, 2019–2025

Across 50 payments — averaging $26.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • OPKO Pharmaceuticals, LLC$616
  • Amgen$281
  • Fresenius USA Marketing, Inc.$220
  • Travere Therapeutics, Inc.$88
  • Akebia Therapeutics Inc$85
  • Vifor Pharma, Inc.$20

What the payments were for

  • Food & beverage$1,309100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,309 in reported general payments places this provider in the 55th percentile of 253 nephrology providers in Missouri.

See all nephrology providers in Missouri

Medicare billing

Part B allowed, 2024
$50,423
Medicare patients
27
Services billed
244

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide35$119,073
Sevelamer Carbonate80$12,058
Lanthanum Carbonate15$11,310
EliquisApixaban18$8,893
Megestrol Acetate14$1,711
Calcium Acetate27$1,586
Midodrine Hcl17$704
Labetalol Hcl30$537
Gabapentin69$455
Tramadol Hcl58$412
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen15$345
Carvedilol55$242
Fluticasone Propionate17$210
Albuterol Sulfate HfaAlbuterol Sulfate11$204
Escitalopram Oxalate28$182

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$220$119,07335 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 253 nephrology providers in Missouri.

Other nephrology in Richmond Heights

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →